CRA was retained by plaintiff in a matter involving the alleged infringement of patents associated with extended-release formulations of a pain management product. CRA reviewed existing and similar licenses for their relevance to determining a royalty range for the hypothetical negotiation between willing parties. CRA then conducted a Georgia-Pacific analysis to provide an opinion on the reasonable royalty assuming the patents were valid and infringed. A key consideration was how extended-release technologies enabled a long-acting formulation that became widely used and favored over short-acting versions.
IP Literature Watch: September 2022
Among the pieces featured in this month’s IP Literature Watch are a paper discussing the licensing of 5G SEPs by automotive manufacturers; an essay exposing...